ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Ankylosing spondylitis (AS)"

  • Abstract Number: L11 • ACR Convergence 2020

    Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

    Atul Deodhar1, Paula Sliwinska-Stanczyk2, Huji Xu3, Xenofon Baraliakos4, Lianne Gensler5, Dona Fleishaker6, Lisy Wang6, Joseph Wu6, Sujatha Menon6, Cunshan Wang6, Oluwaseyi Dina7, Lara Fallon8, Keith S Kanik6 and Désirée van der Heijde9, 1Oregon Health & Science University, Portland, OR, 2Reumatika Centrum Reumatologii, Warszawa, Poland, 3Shanghai Changzheng Hospital, Shanghai, China (People's Republic), 4Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Bochum, Germany, 5University of California San Francisco, San Francisco, CA, 6Pfizer Inc, Groton, CT, 7Pfizer Inc, New York, NY, 8Pfizer Inc, Montreal, QC, Canada, 9Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for the treatment of adult patients (pts) with AS.Methods: This Phase 3, randomized, double-blind…
  • Abstract Number: 0366 • ACR Convergence 2020

    Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab

    Philip Mease1, Atul Deodhar2, Renato Calheiros3, Xiangyi Meng4, Todd Fox5 and Xenofon Baraliakos6, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Oregon Health & Science University, Portland, OR, 3Novartis Pharmaceuticals Corporation, Hoboken, NJ, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, 5Novartis Pharma AG, Aesch, Switzerland, 6Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton associated with pain, stiffness, and disability.1 Up to 66% of patients (pts)…
  • Abstract Number: 1226 • ACR Convergence 2020

    Outcomes and Efficacy of Selective versus Automatic Switching from Etanercept to a Biosimilar in Inflammatory Arthritis Using Electronic Health Records from UK

    Roxanne Cooksey1, Sinead Brophy1, Muhammad Azizur1, Jonathan Kennedy1 and Ernest Choy2, 1Swansea University, Swansea, Wales, United Kingdom, 2CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: Biosimilars have been approved for the treatment of inflammatory arthritis and evidence from randomised controlled trials have demonstrated equivalent efficacy to biologics.  Etanercept biosimilar,…
  • Abstract Number: 1338 • ACR Convergence 2020

    Identification of Muscle Associated Key Genes to Support Axial Spondyloarthritis Diagnosis by Transcriptomic Approach, the MyoSpA Study

    Atlas Mashayekhi Sardoo1, Daniel Sobral2, Lucia Domingues3, Santiago Rodrigues-Manica4, Rita Pinheiro Torres4, Agna Neto5, Ana Filipa Fernandes6, Patricia Alves7, Julia Costa6, Ana Rita Grosso2, Celso Cunha8, Jaime Branco9 and Fernando M Pimentel-Santos4, 13. CEDOC, NOVA Medical School, Faculdade de Ciências Médicas da Universidade NOVA de Lisboa, Lisboa, Portugal, Lisbon, Portugal, 2Faculty of Science and Technology, Universidade Nova de Lisboa, Caparica, Portugal, 3NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal, 4CHLO, Hospital Egas Moniz, Lisbon, Portugal, 51. Rheumatology Department, Hospital Central do Funchal, Madeira, Portugal. 2. Hospital de Egas Moniz, CHLO, Lisbon, Portugal. 3. CEDOC, NOVA Medical School, Lisbon, Portugal, Lisbon, Portugal, 6ITQB-NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Oeiras, Portugal, 7IBET - Institute of Experimental Biology and Technology, Oeiras, Portugal, 8Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa, Lisbon, Portugal, 92. Hospital de Egas Moniz, CHLO, Lisbon, Portugal. 3. CEDOC, NOVA Medical School, Lisbon, Portugal, Lisbon, Portugal

    Background/Purpose: Early diagnosis of axial Spondyloarthritis (axSpA) represents a major clinical challenge nowadays. Increasing evidence has determined that early diagnosis, prompt treatment initiation and early…
  • Abstract Number: 1849 • ACR Convergence 2020

    Identification of New Associations Between Psoriatic Arthritis and the Gut Microbiota. the Mi-PART, a Phenomic Study

    Jesus Miguens Blanco1, Uma Selvarajah1, Zhigang Lui1, Benjamin Mullish1, James Alexander1, Julie McDonald2, Sonya Abraham1 and Julian Marchesi1, 1Imperial College London, London, United Kingdom, 2Imperial College London, London

    Background/Purpose: Perturbations of the gut microbiota have been associated with Psoriatic Arthritis (PsA), a chronic inflammatory disease. We aim to test the microbiome-metabolic interface of…
  • Abstract Number: 1884 • ACR Convergence 2020

    Disease Activity in an Axial Spondyloarthritis Cohort During the COVID-19 Pandemic

    Jean Liew1, Maria Castillo2, Ethan Zaccagnino2, Patricia Katz3, Nigil Haroon4 and Lianne Gensler5, 1University of Washington, Seattle, WA, 2UCSF, San Francisco, CA, 3University of California, San Francisco, Novato, CA, 4University of Toronto, Toronto, ON, Canada, 5University of California San Francisco, San Francisco, CA

    Background/Purpose: Response to the global coronavirus disease (COVID-19) pandemic has resulted in shelter-in-place orders and major changes to how people go about their daily lives.…
  • Abstract Number: 2024 • ACR Convergence 2020

    Effects of Filgotinib on Spinal Lesions in Patients with Ankylosing Spondylitis: Magnetic Resonance Imaging Data from the Placebo-Controlled, Double‑Blind, Randomized TORTUGA Trial

    Walter Maksymowych1, Mikkel Østergaard2, Robert Landewé3, William Barchuk4, Ke Liu4, Chantal Tasset5, Leen Gilles5, Thijs Hendrikx6, Robin Besuyen6 and Xenofon Baraliakos7, 1University of Alberta, Edmonton, AB, Canada, 2Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, 3Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, 4Gilead Sciences, Inc., Foster City, CA, 5Galapagos NV, Mechelen, Belgium, 6Galapagos BV, Leiden, Netherlands, 7Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany

    Background/Purpose: The oral, selective Janus kinase 1 inhibitor filgotinib (FIL) significantly improved Spondyloarthritis Research Consortium of Canada (SPARCC) MRI inflammation scores (bone marrow edema) in…
  • Abstract Number: 0369 • ACR Convergence 2020

    Effect of Upadacitinib on Reducing Pain in Patients with Active Ankylosing Spondylitis and Inadequate Response to Nonsteroidal Anti-inflammatory Drugs

    Atul Deodhar1, Xenofon Baraliakos2, Iain McInnes3, Kurt de Vlam4, Louis Bessette5, Anna Maniccia6, Ralph Lippe7, Christopher Saffore6, Tianming Gao6, In-Ho Song6 and Andrew Östör8, 1Oregon Health & Science University, Portland, OR, 2Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, 3Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 4Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium, 5Laval University, Quebec, Canada, 6AbbVie Inc., North Chicago, IL, 7AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 8Cabrini Medical Center, Monash University, Malvern, Victoria, Australia

    Background/Purpose: Pain is a debilitating symptom of ankylosing spondylitis (AS) and negatively impacts patient (pt) lives. Upadacitinib (UPA), a Janus kinase (JAK) inhibitor engineered for…
  • Abstract Number: 1303 • ACR Convergence 2020

    Performance of Three Referral Algorithms for Diagnosing Axial Spondyloarthritis: Results from the Screening in Axial Spondyloarthritis for Psoriasis, Iritis, and Colitis Cohort

    Ulrich Weber1, Raj Carmona2, James Yeung3, Jon Chan4, Liam Martin5, Ariel Masetto6, Stephanie Keeling7, Olga Ziouzina5, Sherry Rohekar8, Rana Dadashova9, Joel Paschke9, Amanda Carapellucci9, Robert G Lambert10, Walter Maksymowych7 and Sibel Aydin11, 1University of South Denmark, Odense, Denmark, 2St. Joseph's Healthcare, Hamilton, ON, Canada, 3James Yeung Rheumatology, Vancouver, BC, Canada, 4Artus Health Clinic, Vancouver, BC, Canada, 5University of Calgary, Calgary, AB, Canada, 6University of Sherbrooke, Sherbrooke, QC, Canada, 7University of Alberta, Edmonton, AB, Canada, 8Lawson Health Research Institute, London, ON, Canada, 9CARE Arthritis, Edmonton, AB, Canada, 10University of Alberta and CARE Arthritis, Edmonton, AB, Canada, 11University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada

    Background/Purpose: Patients presenting with back pain and psoriasis, acute anterior uveitis (AAU), or inflammatory bowel disease (IBD), represent a high-risk population for the presence of…
  • Abstract Number: 1346 • ACR Convergence 2020

    Predicting Major Treatment Response to Tumor Necrosis Factor Inhibitorsin Patients with Ankylosing Spondylitis

    Runsheng Wang1, Abhijit Dasgupta2 and Michael Ward3, 1Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, 2NIAMS, Bethesda, 3National Institutes of Health, Bethesda, MD

    Background/Purpose: The treatment response to tumor necrosis factor inhibitors (TNFi) in patients with active ankylosing spondylitis (AS) is heterogeneous.  In clinical practice, both patients and…
  • Abstract Number: 1858 • ACR Convergence 2020

    Increased Proportion of TH17, TH22 and TC17 Cells and the Correlation to IL-22 and Clinical Parameters in Patients with Ankylosing Spondylitis from Northern Sweden

    Kristina Lejon1, Urban Hellman2, Lan Do2, Anjani Kumar2 and Helena Forsblad-d'Elia3, 1Department of Clinical microbiology, Infection and Immunology, Umeå University, Umeå, Sweden, 2Department of Public Health and Clinical Medicine, Rheumatology, Umeå, Sweden, 3Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Vasterbottens Lan, Sweden

    Background/Purpose: Increased levels of TH17 and TH22 as well as TC17 and TC22 cells have previously been associated with ankylosing spondylitis (AS). The correlation between…
  • Abstract Number: 1885 • ACR Convergence 2020

    Performance of SASDAS (Simplified Axial Spondyloarthritis Disease Activity Score) versus ASDAS in a Post Hoc Analysis of a Randomized Controlled Clinical Trial

    Emilce Schneeberger1, Gustavo Citera2, Dario Ponce de Leon3, Annette Szumski4, Kenneth Kwok5, Mariel Cutri6 and Maxime Dougados7, 1Department of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3PFIZER, LIMA, Peru, 4Syneos Health, Princeton, 5Pfizer, New York, NY, 6Pfizer, Buenos Aires, Argentina, 7Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France

    Background/Purpose: The Ankylosing Spondylitis Disease Activity Score (ASDAS) assesses axial spondyloarthritis (axSpA) with good internal consistency and discriminative capacity. However, a scientific calculator or electronic…
  • Abstract Number: 0371 • ACR Convergence 2020

    Identifying Inadequate Response Among Ankylosing Spondylitis Patients Prescribed Biologics in a Real-world Commercially Insured Adult Population in the United States

    Theresa Hunter1, Michael Grabner2, Keith Isenberg3, Mingyang Shan4, Chia-Chen Teng2, Jeffrey Lisse4 and Jeffrey R Curtis5, 1Eli Lilly and Company, Indianapolis, 2Healthcore, Inc, Wilmington, DE, 3Anthem, Inc, Indianapolis, IN, 4Eli Lilly and Company, Indianapolis, IN, 5Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The purpose of this analysis was to assess the frequency of inadequate response (IR) over 1 year from biologic initiation among ankylosing spondylitis (AS)…
  • Abstract Number: 1305 • ACR Convergence 2020

    Is the Occurrence of Acute Anterior Uveitis Linked Primarily to Ankylosing Spondylitis (AS) or to HLA-B27? Results of a 35-Year Follow-Up Family Study of a Swiss Cohort of Patients with AS

    Sjef van der Linden1, Peter Villiger2, Zhixiu Li3, Matthew Brown4, Heinz Baumberger5, Hermine Zandwijk6 and Muhammad Khan7, 1Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, 2Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, 3Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, 4Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, 5Retired, Flims, Tajikistan, 6Retired, Mortroux, Belgium, 7Case Western Reserve University, Cleveland OH, Westlake, OH

    Background/Purpose: Approximately 30% of HLA-B27(+) patients with ankylosing spondylitis (AS) have one or more episodes of acute anterior uveitis (AAU), a condition that is also…
  • Abstract Number: 1354 • ACR Convergence 2020

    The Effect of 8 Years of TNF-α Blocking Therapy on Bone Mineral Density in Patients with Ankylosing Spondylitis

    Mark Siderius1, Freke Wink1, Anneke Spoorenberg1 and Suzanne Arends1, 1University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands

    Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease that mainly affects the axial skeleton. Bone loss reflected by low bone mineral density (BMD) is…
  • 1
  • 2
  • 3
  • …
  • 41
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.